Micro
Aftermath
Archived
AMGN Billionaire Ken Fisher's Top 15 Moves
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
7
Sources
2
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Healthcare | -5.6% |
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Related Articles
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Healthcare | -5.6% |
🤖
AI Overview
What happened: Amgen Inc. (NASDAQ:AMGN) has seen a surge in bullish sentiment from analysts and investors. Morgan Stanley raised its price target to $326, while Wells Fargo increased theirs to $390. These moves follow Amgen's announcement that its drug Repatha® showed significant cardiovascular benefits. Billionaire Ken Fisher also doubled his bullish position in Amgen.
Market impact: This positive sentiment has driven up Amgen's stock price, benefiting shareholders. The biotech sector, particularly companies with strong pipelines like Amgen, may see increased investor interest. Meanwhile, BTG Pactual's cautious stance on Tyson Foods (NYSE:TSN) highlights a contrasting view in another high-dividend stock.
What to watch next: Amgen's Q1 earnings, scheduled for April 27, will provide insights into the company's financial health and pipeline progress. Additionally, the FDA's decision on Amgen's Aimovig® label expansion, expected in Q2, could further impact the stock. Lastly, investors will monitor Ken Fisher's continued activity in Amgen's stock.
Market impact: This positive sentiment has driven up Amgen's stock price, benefiting shareholders. The biotech sector, particularly companies with strong pipelines like Amgen, may see increased investor interest. Meanwhile, BTG Pactual's cautious stance on Tyson Foods (NYSE:TSN) highlights a contrasting view in another high-dividend stock.
What to watch next: Amgen's Q1 earnings, scheduled for April 27, will provide insights into the company's financial health and pipeline progress. Additionally, the FDA's decision on Amgen's Aimovig® label expansion, expected in Q2, could further impact the stock. Lastly, investors will monitor Ken Fisher's continued activity in Amgen's stock.
AI Overview as of Apr 16, 2026
Timeline
First SeenMar 19, 2026
Last UpdatedMar 19, 2026